Resa Schlossberg is head of Skadden’s intellectual property and technology transactions practice. She advises clients in numerous industries on a wide range of IP-related issues, focusing on life sciences and technology-intensive representations. Her knowledge of molecular biophysics and biochemistry and research experience allow her to understand the scientific and technical aspects of matters.
Schlossberg structures, drafts, negotiates and advises on joint ventures, strategic alliances, mergers and acquisitions, and agreements such as license, research and development (R&D), collaboration, co-marketing and co-promotion, manufacturing and supply, R&D funding, synthetic royalty deals and consulting. She also conducts IP diligence and evaluates technologies for clients, including pharmaceutical, chemical, biotechnology, cosmetic, medical device and renewable energy companies, among others.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Global IP Lawyers | 2026 | IP, Patent, IP Transactions |
| The 2026 Lawdragon 500 Leading Lawyers in America | 2026 | Tech Transactions, IP Litigation |
| The 2026 Lawdragon 500 Leading Dealmakers in America | 2026 | Tech Transactions, IP |
| The Inaugural Lawdragon 500 Leading Global IP Lawyers | 2025 | Litigation, IP, Patent |
In addition to transactional work, Schlossberg has significant experience litigating patent infringement disputes in U.S. federal court, representing clients in false advertising and consumer deception matters and counseling on various strategic IP issues. She is a registered patent attorney with the U.S. Patent and Trademark Office.
Representative transactions include:
- Achillion in its $930 million sale to Alexion
- Alcon in its $753 million acquisition of Aerie Pharmaceuticals, Inc. and its $355 million acquisition of the U.S. commercialization rights to SIMBRINZA from Novartis AG
- Alnylam Pharmaceuticals, Inc. in its $2.8 billion co-development and co-commercialization agreement with Roche Holding AG to develop and commercialize its hypertension drug Zilebesiran
- Amicus Therapeutics, Inc. in ARYA Sciences Acquisition Corp IV’s acquisition of Amicus’ gene therapy business
- ArQule in its $2.7 billion sale to Merck
- Aspen Technology in its $11 billion merger with Emerson Electric Company’s software business units
- Brookfield Super-Core Infrastructure Partners in its $2.4 billion acquisition of a 19.9% minority interest in FirstEnergy Transmission, LLC
- CerSci Therapeutics Inc. in its acquisition by ACADIA Pharmaceuticals Inc. for $53 million upfront and contingent payments of $887 million
- DENTSPLY SIRONA Inc. in its $131 million acquisition of substantially all of the assets of Propel Orthodontics, LLC
- Dover Corporation in the pending $2 billion sale of its Environmental Solutions Group business to Terex Corporation
- DuPont in several matters, including its merger of its Nutrition and Health Business with IFF through a reverse Morris trust transaction; $11 billion sale of the majority of its Mobility & Materials (M&M) business to Celanese Corp.; and sale of a portion of its crop protection business to FMC Corporation in exchange for substantially all of FMC’s health and nutrition business and a balancing payment of $1.625 billion
- EyeBio in its acquisition by Merck for a $1.3 billion upfront payment and up to $1.7 billion in future milestone payments equaling a potential value of $3 billion
- Gilead Sciences in its $4.9 billion acquisition of Forty Seven, $11.9 billion acquisition of Kite Pharma and acquisition of Cell Design Labs for up to $567 million
- Hasbro in its $522 million acquisition of Saban Brands’ “Power Rangers” and other entertainment assets
- Holcim, Ltd. in its pending separation of its North American businesses into a new stand-alone company
- Iora Health in its $2.1 billion acquisition by One Medical
- Lyell Immunopharma, Inc. in its acquisition of ImmPACT Bio USA Inc., a privately owned clinical-stage cell therapy company
- Morphosys in its purchase by Novartis for an aggregate of €2.7 billion in cash
- Pandion Therapeutics in its pending $1.8 billion sale to Merck
- Pfizer Inc. in its proposed $160 billion combination with Allergan; proposed but withdrawn $115 billion acquisition of AstraZeneca through the formation of a new U.K. holding company; IPO of its animal health business and related R&D collaboration and license agreement and IP license agreements between Pfizer Inc. and Zoetis Inc.; R&D agreements with NovaQuest and RPI Finance Trust; exclusive agreement granting AROG Pharmaceuticals worldwide rights to a small molecule inhibitor of PDGFr; and collaboration to co-develop Tremelimumab for advanced melanoma
- Purdue Pharma L.P. in its sale of an active pharmaceutical ingredient (API) manufacturing facility and corresponding negotiation of a long-term API supply agreement with the facility purchaser and an agreement with stalking horse bidder Atlantis Consumer Healthcare to sell the assets of Avrio Health L.P. for up to $397 million via an auction process pursuant to Section 363 of the Bankruptcy Code
- Unilever in its pending acquisition of Grüns Nutrition, Inc.
- Vertex Pharmaceuticals in its $950 million acquisition of Semma Therapeutics and $320 million acquisition of ViaCyte